AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04890171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Gastrectomy with lymph node dissection by a surgeon
Study NCT06350279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK39297
Description: 50-600mg
Study NCT05135390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542
Description: three times per week
Study NCT05135390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: three times per week
Study NCT04550845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus group analyses
Description: Focus group audiotapes will be transcribed verbatim, and then entered into the qualitative data software package, NVivo 14 for analysis.
Study NCT05660083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: Patients with HER2 negative metastatic or locally advanced MpBC, will receive a combination of an iNOS inhibitor, nab-paclitaxel and alpelisib . As prophylaxis against deep venous thrombosis and hypertension, patients will receive aspirin (81 mg po daily) and amlodipine (10 mg po Days 0-5 each cycle). Metformin will be initiated at 500 mg once daily starting one week prior to treatment to reduce risk of severe hyperglycemia. Based on tolerability and serial blood sugar assessments, metformin dose will be increased to 500 mg twice daily, followed by 500 mg with breakfast and 1000 mg with dinner, followed by further increase to 1000 mg twice daily if needed. Insulin sensitizers and/or SGLT2i will be used as second anti-diabetic agents, if necessary. For prophylaxis of alpelisib rash, patients will be treated with an anti-histamine (cetirizine 10 mg daily) along with alpelisib.
Study NCT05151978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler
Description: Transcranial Doppler on middle cerebral arteries
Study NCT05262920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The BSM Intervention
Description: The BSM intervention entailed a daily electronic journal for monitoring BF and BNP with feedings, bi-weekly texting for 6 weeks from a research nurse for informational support and to promote personalized goal-setting and problem-solving, and hyperlinks to eight uniform BNP educational modules (knowledge and skills) and online resources. 1. Fundamentals of BF (FBF), 2. Deep breathing (DB), 3. BNP non-pharmacological strategies (BNPS), 4. Guided imagery (GI), 5. Pain neurophysiology specifically related to BF (PN-BF), 6. Catastrophizing, 7. Stress reactivity, and 8. Common pumping issues and interventions (CPI).
Study NCT05262920 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: The Attention Control and Intervention groups both receive fourth-trimester care videos. The educational modules are the following: Urgent maternal warning signs, caring for the maternal body after birth; infant care; COVID-19 and infant health prevention; maternal and infant immunization; infant safety in the home; maternal and infant dietary recommendations; and national and health resources to support BF in the workplace
Study NCT06202547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-ovarian injection of bone marrow mesenchymal stromal cells-derived extracellular vesicles
Description: he patient is anesthetized and placed in a lithotomy position, after preparing and washing the vagina with normal saline, under transvaginal ultrasound guidance (Aloka-40000 vaginal probe, Japan) using needle puncture (Reproline medical Gmbh, Rheinbach/Germany). The injection of 2 ml of extracellular vesicles derived from MSCs (equivalent to 30 million cells) will be performed into one ovary of the patient (the accessible ovary).
Study NCT05653609 — intervention group
Intervention type: DEVICE
Intervention: Cureety TechCare
Description: Weekly adverse event questionnaires completed by the patients using a digital tool called Cureety
Study NCT05591378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stability exercises
Description: exercises for 8 weeks and 3 individual sessions per week for 30-45 minutes. Each exercise will be given for 3 to 5 minuts.~first week:Cat camel stretch, all fours stretch and lifting one leg, cobra pose, lying on your back and raising the legs/one leg, and hamstring stretch on chair second week:Straight Leg Crunch, with first week exercises third week:Crunch, bridge exercise,and lifting the legs/one leg straight out with first week exercises fourth week:lifting the legs/one leg to the opposite hand, with first week exercises fifth week:Reverse Crunch, bridge exercise without support with first week exercises sixth week:Hamstring stretch on the Floor with first week exercises seventh week:lifting one hand and one leg, with first week exercises eight week:Exercise Ball Crunch,and stability ball bridge with first week exercise
Study NCT05591378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: otago exercises
Description: exercises for 8 weeks and 3 individual sessions per week for 30-45 minutes. Each exercise will be given for 3 to 5 minuts.~Walking forward with support, standing on heel with support, side walking with support, standing on one foot with support.Walking forward without support, standing on heel without support, side walking without support, standing on one foot without support.~Walking backward with support, walking on heel with support, walking and turning around, walking on heel with support.~Walking backward without support, walking on heel without support, walking and turning around, walking on heel without
Study NCT05016674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipoLife system
Description: Abdominal Laser-Assisted Liposuction
Study NCT06512116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP-A17
Description: Strength: 1, 2, 4, 5, 6 or 8 mg. Intravenous infusion administration, with a treatment cycle of every 21 days, administered once on the first day of each cycle.~The dose escalation stage, 1mg/kg and 2mg/kg were subjected to accelerated titration, where the safety was evaluated within 21 days after the first administration to one subject. If dose-limiting toxicity (DLT) occurred, the traditional 3+3 dose escalation method was immediately switched. If DLT does not occur, the next dose group will be explored, and the dose exploration starting from 4mg/kg will adopt a 3+3 dose escalation design.
Study NCT04815707 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Occcult hernia repair
Description: The occult hernia will be repaired during the same inguinal hernia repair
Study NCT06134427 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: basic combat training (investigator did not design the intervention)
Description: 12 weeks basic combat training is 12 weeks is a compulsory program for all cadets accepted in republic indonesia defense university
Study NCT05521269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX1502
Description: ANX1502 is a prodrug of ANX1439.
Study NCT05521269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator.
Study NCT04013802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-matched VSTs
Description: An alternative approach that bypasses the need to grow VSTs for individual patients is to bank closely HLA-matched allogeneic VSTs that could be available as an off the shelf product.~The HLA-matched VST product is to produce immune activity to CMV, Adv, BK virus and EBV in all recipients.~Most recently our group extended this off the shelf approach to five viruses using the T cell product manufactured in 10 days. The VSTs were administered to 38 patients with 45 infections in a phase II clinical trial. A single infusion produced a cumulative complete or partial response rate of 92% overall and the following rates by virus: 100% for BKV (n = 16), 94% for CMV (n = 17), 71% for AdV (n = 7), 100% for EBV (n = 2), and 67% for HHV-6 (human herpesvirus) (n = 3).
Study NCT06458400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegileridine
Description: single dose+PCA dose
Study NCT06458400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine
Description: single dose+PCA dose
Study NCT06458400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: single dose+PCA dose
Study NCT05429827 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Inject 2 ml normal saline into a myofascial trigger point and evaluate the clinical effects before and after the injection.
Study NCT05429827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 5% in water
Description: Inject 2 ml 5% dextrose into a myofascial trigger point and evaluate the clinical effects before and after the injection.
Study NCT05429827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 15% in water
Description: Inject 2 ml 15% dextrose into a myofascial trigger point and evaluate the clinical effects before and after the injection.
Study NCT03915327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous iron isomaltose anhydride
Description: Enrolled subjects would receive intravenous iron isomaltose anhydride within 24 hours of the subject's inclusion.
Study NCT05927571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab solution for infusion will be administered as IV as specified in each treatment arm.
Study NCT05927571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Elranatamab solution for injection will be administered SC as specified in each treatment arm.
Study NCT05927571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.
Study NCT05331300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LASN01
Description: Escalating single and multiple doses of LASN01
Study NCT05331300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LASN01
Description: LASN01 will be administered intravenously
Study NCT06183385 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Saliva collection
Description: Collection of 2 samples of 1.5 to 2mL of saliva by passive salivation in healthy volunteers
Study NCT06183385 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vaginal secretion collection
Description: Collection of vaginal secretions with 2 dry swabs in women
Study NCT06183385 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IP-LC-MS/MS : immunoprecipitation enrichment with liquid chromatography coupled to tandem mass spectrometry
Description: sample preparation and analysis :~* Impregnation of the tips (absorbent cotton) of sterile dry swabs and vaginal swabs with controlled quantities of saliva.~* Immunocapture of salivary proteins of interest (histatin type 1, cystatin D, PRPs) by protein A affinity purification~* LC-MS/MS analysis of eluted purified peptides (Multiple Reaction Monitoring mode)~Dilutions will be made from 10 to 10 (1/10, 1/100, 1/1000...), then after reaching a detectability threshold, specified by a second more precise analysis (e.g. if no signal at 1/1000, analysis at 1/500 then 1/250 etc.). Analytical sensitivity will be tested on three samples of each type (salivary, vaginal, vaginal + semen) to ensure reproducibility of results.~Operators, unaware of the presence of saliva in the samples, will then carry out saliva-specific protein detection analysis using the IP-LC-MS/MS method.
Study NCT05331300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Escalating doses of matching placebo
Study NCT05331300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously
Study NCT05960604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Passive leg raising
Description: All patients who met the inclusion criteria will be placed head down flat and feet up at a 45° angle for 30 seconds.~Hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected before, during and after the test until the end of the surgery.~The total duration of the intervention (passive leg raising) is 30 seconds. The total duration of hemodynamic parameters recording is expected to be 60-600 minutes.
Study NCT05713617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PODER Familiar
Description: Educational intervention designed to improve healthy behaviors of families of children with intellectual and developmental disabilities.
Study NCT05726929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Description: Osteopathic Manual Treatment
Study NCT05726929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsaicin QUTENZA Patch (TAU)
Description: Capsaicin QUTENZA Patch is the treatment as usual (TAU) delivered in the medical algology service
Study NCT05726929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin QUTENZA Patch (TAU)
Description: Capsaicin QUTENZA Patch is the treatment as usual (TAU) delivered in the medical algology service
Study NCT05835895 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GNSC-001
Description: intra-articular injection
Study NCT05835895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transient immune-modulation
Description: oral
Study NCT05835895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transient immune-modulation
Description: intra-articular injection
Study NCT05835895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intra-articular injection
Study NCT05012696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Description: Non-invasive ventilation will be provided through a mechanical ventilator (Carina, Dräger) through a facial interface (Fitlife Respironics, Philips). A PEEP level between 5 and 10 cmH2O, minimal pressure-support level of 5 cm H2O targeting a tidal volume around 6 to 8 ml/kg and at the same FiO2 applied during the spontaneous breathing trial.
Study NCT05517148 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Therapeutic VR
Description: Treatment module categories included: (1) Mindfulness-based stress reduction training: an audio conducting practice with breathing-based biofeedback training in immersive and interactive environments to support self-regulation and relaxation.
Study NCT05517148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic VR
Description: Treatment module categories included: (1) Mindfulness-based stress reduction training: an audio conducting practice with breathing-based biofeedback training in immersive and interactive environments to support self-regulation and relaxation.
Study NCT05143346 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intubation
Description: Using video stylet and video laryngoscope in difficult intubation in patients with trauma or suspected to be have difficult intubation.
Study NCT05446857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir / Pibrentasvir Pill
Description: Glecaprevir 100 mg/Pibrentasvir 40 mg, 3 oral tablets once daily for 8 weeks.
Study NCT05138588 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: For each subject, a verum condition and a control condition will be programmed. We will use the QPS-5 method (4 pulses, Inter-Stimulation Interval; ISI: 5 seconds).
Study NCT05138588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: For each subject, a verum condition and a control condition will be programmed. We will use the QPS-5 method (4 pulses, Inter-Stimulation Interval; ISI: 5 seconds).
Study NCT01535521 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sleep Position Trainer (SPT)
Study NCT06343467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generic Volar Locking Plate
Description: Application of a generic volar locking plate is done in the generic implant arm compared to the other commonly used implants by surgeons in the conventional implant arm.
Study NCT06343467 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Volar Locking Plate
Description: Application of a conventional, brand name volar locking plate is done in the conventional implant arm compared to the generic implant arm.
Study NCT05012696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Description: High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher \& Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.
Study NCT03734731 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Monochromatic Infrared Photo Energy (MIRE)
Description: Apply Monochromatic Infrared Photo Energy (MIRE) to the affected nerve
Study NCT03734731 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Apply Transcutaneous Electrical Nerve Stimulation (TENS) to the affected nerve
Study NCT03734731 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Opioids
Description: Prescribe Opioids to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator
Study NCT03734731 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cannabis
Description: Prescribe Cannabis to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator. Comparing Opioid results to Cannabis results with objective nerve testing
Study NCT04547985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone HCl 50 MG Oral Tablet
Description: Generic, oral tablet.
Study NCT04547985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Composed of filler material and encapsulated to appear identical to naltrexone.
Study NCT04831411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: The extremities of patients admitted to the operating room to be applied TKA will be determined using a safe surgical Fast-Track recovery protocol. Patients will be operated by the same surgical team using the same technique. Spinal anaesthesia or general anaesthesia will be applied to the patients according to the evaluations of the anesthesiologists.
Study NCT05590819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation(rTMS)
Description: 5 hertz(Hz), 1000 pulses, 90% RMT stimulation; 15 minutes per session; for a total of 10 sessions
Study NCT05590819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta-burst Stimulation(iTBS)
Description: 3 pulses of stimulation delivered at 50 Hz and repeated at 5 Hz; 2s train of TBS with repetitive interval of every 10s, 70% RMT; 600 pulses in total; 15 minutes per session; for a total of 10 sessions
Study NCT05590819 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Description: Set-up the coil without true stimulation; 15 minutes per session; for a total of 10 sessions
Study NCT05812651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle fatigue
Description: Muscle training according to the protocol that tends to induce inspiratory muscle fatigue. (60-80% MIP). Inspiratory resistive loading by starting at 60-80% (MIP) increasing every 10 minutes by 10% then measure MIP, until MIP measurement decrease of more than 10% from baseline will be performed.~When report a lower score of MIP and participants could no longer worked out, performed the functional mobility tests and see if there any variation.
Study NCT05594979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TOTUM-070
Description: 2.5-g dose of TOTUM-070 diet supplement; Four capsules per day to consume orally in two intakes
Study NCT04831411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Vibration
Description: Whole Body Vibration
Study NCT04831411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Resistance Training
Description: Progressive Resistance Training
Study NCT06456346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Oral capsule
Study NCT06456346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Oral capsule
Study NCT06456346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bomedemstat placebo
Description: Oral capsule placebo
Study NCT06456346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea placebo
Description: Oral capsule placebo
Study NCT05965518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.
Study NCT05965518 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Moderate Exercise
Description: Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak, followed by a 4 minute cool-down. The total exercise time is 50 minutes.
Study NCT05574569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1: Play Therapy
Description: Play therapy will be given to children having emotional and behavioral problems.
Study NCT05574569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 2: Mindful Parenting
Description: Culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.